• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by KalVista Pharmaceuticals Inc.

    2/12/24 8:30:49 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KALV alert in real time by email
    SC 13G 1 tm245941d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Kalvista Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    483497103

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x  Rule 13d-1(b)
    ¨  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Continued on following pages

    Page 1 of 7 Pages

     

     

     

     

     

     

    CUSIP NO. 483497103 Page 2 of 7 Pages

     

    CUSIP No.  483497103
    (1)   Names of reporting persons Saturn V Capital Management LP
    (2)  Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3)  SEC use only  
    (4)  Citizenship or place of organization DE
    Number of shares beneficially owned by each reporting person with:  
    (5)  Sole voting power 0
    (6)  Shared voting power 1,431,259*
    (7)  Sole dispositive power 0
    (8)  Shared dispositive power 1,431,259*
    (9)  Aggregate amount beneficially owned by each reporting person 1,431,259*
    (10)  Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11)  Percent of class represented by amount in Row (9) 4.1%†
    (12)  Type of reporting person (see instructions) IA

     

    * Saturn V Capital Management LP acts as the investment manager of certain pooled investment vehicles and managed accounts (collectively the “Clients”) in which such shares referred to above are held. As a result, Saturn V Capital Management LP possesses the power to vote and dispose or direct the disposition of all the shares beneficially owned by the Clients. No Client holds or beneficially owns five percent or more of the outstanding shares of the Issuer. Saturn V Capital Management LP disclaims beneficial ownership of any of the shares held by the Clients.

     

    † Based on a total of 34,558,709 shares outstanding of the Issuer as of November 30, 2023, as set forth in the Issuer’s most recent Form 10-Q, filed December 7, 2023.

     

     

     

     

    CUSIP NO. 483497103 Page 3 of 7 Pages

     

    CUSIP No.  483497103
    (1)  Names of reporting persons Xiaoying Tian
    (2)  Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3)  SEC use only  
    (4)  Citizenship or place of organization United States of America
    Number of shares beneficially owned by each reporting person with:  
    (5)  Sole voting power 0
    (6)  Shared voting power 1,431,259*
    (7)  Sole dispositive power 0
    (8)  Shared dispositive power 1,431,259*
    (9)   Aggregate amount beneficially owned by each reporting person 1,431,259*
    (10)  Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11)  Percent of class represented by amount in Row (9) 4.1%†
    (12)  Type of reporting person (see instructions) IN, HC

     

    * Ms. Tian is the Managing Member of SVCM GP LLC, the general partner of Saturn V Capital Management LP, the Investment Manager of the Clients. As a result, Ms. Tian possesses the power to vote and dispose or direct the disposition of all the shares beneficially owned by the Clients. Ms. Tian disclaims beneficial ownership of any of the shares held by the Clients.

     

    † Based on a total of 34,558,709 shares outstanding of the Issuer as of November 30, 2023, as set forth in the Issuer’s most recent Form 10-Q, filed December 7, 2023.

     

     

     

     

    CUSIP NO. 483497103 Page 4 of 7 Pages

     
    Item 1(a). Name of Issuer:
       
      Kalvista Pharmaceuticals, Inc. (the “Issuer”).
       
    Item 1(b). Address of the Issuer's Principal Executive Offices:
       
      55 Cambridge Parkway, Suite 901E, Cambridge, MA 02142.
       
    Item 2(a). Name of Person Filing
       
     

    The names of the person filing this statement on Schedule 13G (collectively, the “Reporting Persons”) are:

     

    Saturn V Capital Management LP (“Saturn”)
    Xiaoying Tian

       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
      919 Congress Avenue, Suite 830, Austin, TX 78701

     

    Item 2(c). Citizenship:
       
     

    Saturn is a Delaware limited partnership.

    Xiaoying Tian is a United States citizen.

       
    Item 2(d).

    Title of Class of Securities:

       
     

    Common Stock (the “Shares”).

       
    Item 2(e). CUSIP Number:
       
     

    483497103

      

     

     

     

    CUSIP NO. 483497103 Page 5 of 7 Pages

     

    Item 3.

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

       
     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     

    (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);Page 5 of 6 pages

     

    (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J)

       

     Item 4.

    Ownership:

     

     

    The Shares described herein are owned by certain pooled investment vehicles and managed accounts for which Saturn serves as an investment manager. As a result, Saturn and Xiaoying Tian, as the managing member of the general partner of Saturn, may be deemed to beneficially own the Shares for the purposes of Rule 13d-3 of the Act insofar as they may be deemed to have the power to direct the voting or disposition of the Shares.

     

    Neither the filing of this Schedule nor any of its contents shall be deemed to constitute an admission that Saturn, Xiaoying Tian, or any other person is, for any purpose, the beneficial owner of any of the Shares described herein, and such beneficial ownership is expressly disclaimed.

       
    Item 4(a).

    Amount Beneficially Owned:

     

    Aggregate of all Reporting Persons - 1,431,259

     

    Saturn – 1,431,259*

    Xiaoying Tian - 1,431,259**

       
    Item 4(b).

    Percent of Class:

     

    Aggregate of all Reporting Persons – 4.1% †

     

    Saturn – 4.1% †*

    Xiaoying Tian - 4.1% †**

     

     

     

     

    CUSIP NO. 483497103 Page 6 of 7 Pages

     

    Item 4(c). Number of shares as to which such person has:
       
      (i)

    Sole power to vote or direct the vote:

     

    Saturn – 0

    Xiaoying Tian - 0

         
      (ii)

    Shared power to vote or to direct the vote:

     

    Saturn – 1,431,259*

    Xiaoying Tian - 1,431,259**

         
      (iii)

    Sole power to dispose or to direct the disposition of:

     

    Saturn – 0

    Xiaoying Tian - 0

         
      (iv)

    Shared power to dispose or to direct the disposition of:

     

    Saturn – 1,431,259*

    Xiaoying Tian - 1,431,259**

     

    * Saturn acts as the investment manager for the Clients who hold the Shares described herein and referred to above. As a result, Saturn possesses the power to vote and dispose or direct the disposition of all the Shares beneficially owned by the Clients. No Client holds or beneficially owns five percent or more of the outstanding Shares of the Issuer. Saturn disclaims beneficial ownership of any of the Shares held by the Clients.

     

    ** Ms. Tian is the Managing Member of SVCM GP LLC, the general partner of Saturn, the Investment Manager of the Clients. As a result, Ms. Tian possesses the power to vote and dispose or direct the disposition of all the Shares beneficially owned by the Clients. Ms. Tian disclaims beneficial ownership of any of the Shares held by the Clients.

     

    † Based on a total of 34,558,709 shares outstanding of the Issuer as of November 30, 2023, as set forth in the Issuer’s most recent Form 10-Q, filed December 7, 2023.

     

    Item 5. Ownership of Five Percent or Less of a Class:
       
     

    If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be a beneficial owner of more than five percent of the class of securities, check the following: x

       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:
       
      This Item 6 is not applicable.

     

     

     

      

    CUSIP NO. 483497103 Page 7 of 7 Pages

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
       
      This Item 7 is not applicable.
       
    Item 8. Identification and Classification of Members of the Group:
       
      This Item 8 is not applicable.
       
    Item 9. Notice of Dissolution of Group:
       
      This Item 9 is not applicable.
       
    Item 10. Certification:

     

      By signing below the Reporting Person certifies that, to the best of such person's knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: February 12, 2024  
         

    Saturn V Capital Management LP

     
       
       
    By: /s/  Xiaoying Tian  
    Name: Xiaoying Tian  

    Title:

    Managing Member of SVCM GP LLC, the General Partner of Saturn V Capital Management LP
         

    Xiaoying Tian

     
       
       
    By: /s/  Xiaoying Tian  
    Name: Xiaoying Tian  

     

     

     

    Get the next $KALV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KALV

    DatePrice TargetRatingAnalyst
    1/9/2026$32.00 → $35.00Buy
    Needham
    1/6/2026$28.00 → $32.00Buy
    Needham
    1/31/2025$19.00Mkt Outperform
    JMP Securities
    1/7/2025$30.00Buy
    TD Cowen
    12/18/2024$22.00Buy
    BofA Securities
    3/11/2022$48.00 → $42.00Buy
    Needham
    12/10/2021$50.00 → $48.00Buy
    Needham
    More analyst ratings

    $KALV
    SEC Filings

    View All

    SEC Form S-8 filed by KalVista Pharmaceuticals Inc.

    S-8 - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

    1/26/26 5:00:38 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

    1/8/26 4:47:09 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by KalVista Pharmaceuticals Inc.

    SCHEDULE 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    12/30/25 4:28:56 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on KalVista Pharmaceuticals with a new price target

    Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $35.00 from $32.00 previously

    1/9/26 7:49:25 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham reiterated coverage on KalVista Pharmaceuticals with a new price target

    Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $28.00 previously

    1/6/26 7:58:35 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JMP Securities initiated coverage on KalVista Pharmaceuticals with a new price target

    JMP Securities initiated coverage of KalVista Pharmaceuticals with a rating of Mkt Outperform and set a new price target of $19.00

    1/31/25 7:03:28 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $235,500 worth of shares (25,000 units at $9.42) (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    4/11/25 5:22:07 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $1,498,661 worth of shares (161,700 units at $9.27) (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/14/25 7:45:15 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $967,145 worth of shares (104,489 units at $9.26) (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/11/25 7:51:08 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline

    Guideline recommends ensuring on-demand treatment is available anytime, anywhere and prioritizes early intervention and rapid self-administration, reinforcing the unique value of EKTERLY KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced that the newly published International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema recommends EKTERLY® (sebetralstat) as a first-line therapy for the acute treatment of hereditary angioedema (HAE) attacks in adolescents aged 12 years and older.1 Based on robust, high-quality evidence, including clinical trial data demonstrating consistent efficacy, rapid symptom relief and a favorable safety profi

    2/18/26 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the acceptance of three abstracts for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Philadelphia, Pennsylvania from February 27–March 2, 2026. The following poster presentations will take place on Friday, February 27 from 2:45–3:45 pm ET in the Convention Center, Level 2, Hall E: Response Drivers in Sebetralstat Placebo-controlled Clinical Trials: Jonathan Bernstein, Emel Aygören-Pürsün, Danny Cohn, Henriette Farkas, William Lumry, Andrea Zanichelli, James Hao, Matthew Iverson, Michael Smith, Paul Audhya, Erik Hansen, Nathan Teuscher, Marc Riedl. On-demand

    2/12/26 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted six newly-hired employees inducement options to purchase an aggregate of 96,750 shares of KalVista common stock on February 1, 2026 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the first day a closing price is reported following the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each cas

    2/3/26 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Leadership Updates

    Live Leadership Updates

    View All

    KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the appointments of Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, effective October 6, 2025. "I am pleased to welcome Bilal and Linea to our leadership team as we advance the global launch of EKTERLY," said Ben Palleiko, Chief Executive Officer of KalVista. "Their respective expertise in operations and human resources will be instrumental as we deliver on our commitment to people living with HAE." "I am excited to join KalVista and collaborate with such a talented team," said Mr. Arif. "This is a pivotal time for EKTERLY, and I am focused on strengthening the operational framework to ensure pe

    10/6/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the appointment of Bethany L. Sensenig to its Board of Directors, effective as of October 1, 2025. Ms. Sensenig was also appointed a member of the Audit Committee of the Board. In connection with Ms. Sensenig's appointment to the Audit Committee, Nancy Stuart will transition off the Audit Committee but remains a member of the Board and continues to serve on the Nominating and Corporate Governance Committee of the Board. The Board also approved Ms. Stuart's appointment to the Compensation Committee of the Board. "I am pleased to welcome Bethany to the Board of Directors of KalVista. Her extensive financial and operational experti

    10/2/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

    EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to its Board of Directors. "We are delighted to welcome Dr. Reid to our Board of Directors. Laurence brings a remarkable track record as a company builder and biotech executive, with deep experience across business development, research and development strategy, and organizational growth," said Brian C. Thomas, PhD, CEO and founder of Metagenomi. "Laurence's insight and counsel will be invaluable

    8/11/25 4:05:00 PM ET
    $KALV
    $MGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $KALV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Palleiko Benjamin L converted options into 2,419 shares and sold $15,570 worth of shares (1,038 units at $15.00), increasing direct ownership by 0.32% to 429,667 units (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/19/26 7:45:24 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF MEDICAL OFFICER Audhya Paul K. converted options into 2,419 shares and sold $17,445 worth of shares (1,163 units at $15.00), increasing direct ownership by 0.95% to 133,087 units (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/19/26 7:44:40 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF DEVELOPMENT OFFICER Yea Christopher converted options into 1,774 shares and sold $16,635 worth of shares (1,109 units at $15.00), increasing direct ownership by 0.30% to 224,173 units (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/19/26 7:44:07 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Financials

    Live finance-specific insights

    View All

    KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results

    US launch of EKTERLY® gaining strong momentum with $13.7 million in net product revenue for the third quarter 937 patient start forms received through October, reflecting rapid adoption as first and only oral on-demand treatment for hereditary angioedema (HAE) Launched EKTERLY in Germany with initial orders signaling encouraging demand $309M in cash expected to fund the Company through profitability Management to host conference call Tuesday, November 11th at 8:30 a.m. ET KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and reported financial results for the third quarter ended September 30, 2025. "The US launch of EKTERLY is progressing with si

    11/10/25 4:30:00 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) will host a conference call and webcast on Tuesday, November 11, 2025, at 8:30 a.m. ET to review the Company's third quarter financial results and provide an operational update. The live audio webcast will be accessible on the Investors section of the Company's website at www.ir.kalvista.com/event-calendar. An archived replay will be available on the site approximately two hours after completion of the event. About KalVista Pharmaceuticals, Inc. KalVista is a global pharmaceutical company dedicated to delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discovered

    11/3/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

    -EKTERLY® now approved in the US and UK; first and only oral on-demand therapy for acute attacks of hereditary angioedema- -Initiated US EKTERLY launch in July; received 460 patient start forms through August- -European Medicines Agency adopted a positive opinion recommending approval of sebetralstat and confirmed maintenance of orphan designation in EU; decision expected early October- -$191M in cash, providing runway into 2027- -Management to host conference call today at 8:30 a.m. ET- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and released financial results for the fiscal quarter ended July 31, 2025. "This quarter marked a defining mome

    9/11/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

    SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 4:00:06 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

    SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 3:57:49 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by KalVista Pharmaceuticals Inc.

    SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 12:02:33 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care